GC Wealth Management RIA LLC Sells 6,653 Shares of Eli Lilly and Company $LLY

Key Points

• GC Wealth Management RIA LLC trimmed its Eli Lilly stake by 25.3%, selling 6,653 shares and retaining 19,645 shares worth about $21.11 million, making LLY 0.8% of the firm's holdings and its 20th-largest position.
• Eli Lilly beat Q1 estimates with $8.55 EPS (vs. $6.97 expected) and $19.8B revenue, raised FY2026 guidance to $35.50–37.00 EPS and $82–85B revenue, prompting several analyst price-target increases and a MarketBeat consensus of "Moderate Buy" (PT $1,212.96).
• The stock carries a large institutional base (about 82.5% owned), a market cap near $912B and a PE around 34.3, though investors note ongoing competitive, pricing and regulatory risks amid strong GLP‑1 momentum.

GC Wealth Management RIA LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 25.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,645 shares of the company's stock after selling 6,653 shares during the period. Eli Lilly and Company comprises 0.8% of GC Wealth Management RIA LLC's holdings, making the stock its 20th largest position. GC Wealth Management RIA LLC's holdings in Eli Lilly and Company were worth $21,112,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC raised its holdings in shares of Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock valued at $27,000 after purchasing an additional 16 shares during the period. 10Elms LLP raised its holdings in shares of Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after purchasing an additional 10 shares during the period. Miller Global Investments LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at about $33,000. Finally, Hopwood Financial Services Inc. grew its stake in Eli Lilly and Company by 113.6% in the 3rd quarter. Hopwood Financial Services Inc. now owns 47 shares of the company's stock valued at $36,000 after buying an additional 25 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. CICC Research upped their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a "neutral" rating in a research note on Wednesday, February 11th. Bank of America decreased their target price on shares of Eli Lilly and Company from $1,294.00 to $1,133.00 and set a "buy" rating on the stock in a research report on Friday. The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the stock a "buy" rating in a research report on Friday. Cantor Fitzgerald increased their target price on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an "overweight" rating in a research report on Friday. Finally, Jefferies Financial Group set a $1,300.00 target price on shares of Eli Lilly and Company and gave the stock a "buy" rating in a research report on Friday, March 13th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,212.96.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $965.19 on Friday. The company has a 50 day moving average of $947.05 and a 200-day moving average of $986.14. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The company has a market cap of $911.93 billion, a PE ratio of 34.29, a price-to-earnings-growth ratio of 1.13 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 115.33%. The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the firm posted $3.34 EPS. The firm's quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 33.79 earnings per share for the current fiscal year.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 results and guidance boost: Lilly reported roughly $19.8B revenue and $8.55 non‑GAAP EPS (well above consensus), raised 2026 revenue guidance to $82–85B and lifted EPS guidance to $35.50–37 — a primary driver of the rally. Eli Lilly raises annual profit forecast as GLP-1 drugs fuel growth
• Positive Sentiment: Foundayo (oral GLP‑1) early traction: Foundayo — the first oral GLP‑1 with no food/water timing restrictions — has seen early prescriptions (management cites >20,000 patients), supporting longer‑term market share and convenience advantages versus rivals. Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent
• Positive Sentiment: Regulatory tailwind for pricing/protection: The FDA proposed excluding key GLP‑1 active ingredients from the compounding bulk list — a move that would limit cheaper mass compounding and help protect branded volumes/pricing. US FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Street upgrades and higher price targets: Major banks raised price targets and reiterated buy/overweight ratings after the results and guidance, supporting momentum from institutional analysts. Cantor Fitzgerald raises PT
• Neutral Sentiment: Novo’s oral rollout increases scrutiny: Novo Nordisk is expanding its oral GLP‑1 presence (rebranded Rybelsus/Ozempic pills across many pharmacies), a development investors will watch but which hasn’t flipped the narrative away from Lilly yet. Novo Launches Ozempic Pills Across 70,000 US Pharmacies
• Neutral Sentiment: Valuation and long‑term upside debate: Several analyses highlight a tension between Lilly’s strong top‑line growth and a stretched valuation after multi‑year gains; some see material upside if GLP‑1 momentum persists, others caution about multiple compression risk. Eli Lilly Stock’s Path To 30% Upside
• Negative Sentiment: Competitive and pricing pressure risks remain: PBM/insurer negotiation, faster ramps from rivals and longer‑term generic/compounding threats could pressure realized prices and margin expansion — a risk highlighted in market commentary despite the quarter’s beat. Fast Money panel on Novo vs Lilly
• Negative Sentiment: Regulatory / stakeholder friction: Hospital groups have pushed back on certain Lilly data/340B requests, which could create policy or reimbursement friction to monitor. AHA urges HHS to block Lilly 340B data demands

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.